Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCeiba Investme. Regulatory News (CBA)

Share Price Information for Ceiba Investme. (CBA)

Share Price is delayed by 15 minutes
Get Live Data
29.00    0.00 (0.00%)
Bid:
24.00
Ask:
34.00
Spread: 10.00 (41.667%)
Market Cap: £47.91m
CBA Live PriceLast checked at - London Stock Exchange

Intraday Ceiba Investme. Share Chart

Trading Update - Payment to Bondholders

8 Jul 2025 07:00

RNS Number : 0476Q
Ceiba Investments Limited
08 July 2025
 

CEIBA INVESTMENTS LIMITED

(the "Company")

 

(TICKER: CBA, ISIN: GG00BFMDJH11)

Legal Entity Identifier: 213800XGY151JV5B1E88

 

TRADING UPDATE

PAYMENT TO BONDHOLDERS

 

The Board of Directors of the Company is pleased to announce that, notwithstanding the strong headwinds that Cuba, and the Company, are facing, during the first 6 months of 2025, HOMASI S.A., a subsidiary in which the Company has a 65% interest and holds the interests in the Melia Habana, Melia Las Americas, Melia Varadero, Sol Palmeras and Melia Trinidad Península hotels received a total of US$5,108,880 in dividends and US$201,834 in payments under its participation in the TosCuba credit facility. CEIBA MTC Properties Inc., a wholly-owned subsidiary of the Company that holds the Company's interests in the Miramar Trade Center, received a total of US$1,715,000 in dividends. In addition, the Company received US$1,079,450 in payments under its direct participation in the TosCuba credit facility.

 

As a result, on 30 June 2025, the Company paid US$682,125 in deferred management fees to its former asset manager Aberdeen Asset Management Limited ("Aberdeen") and made payments of principal and interest totaling €5,500,000 to holders of the €25 million Convertible Bonds 2029 issued by the Company. In accordance with the (amended) Bond Instrument executed in January 2025, the next payment of principal under the Convertible Bonds (€5 million) is scheduled to be made on or before 31 March 2026.

 

About the Company:

 

CEIBA Investments Limited is a listed closed-end fund dedicated to investing in Cuba, with interests in the commercial and tourism real estate sectors. Its interests include holdings in 2,235 hotel rooms of the Melia Habana (Havana), Melia Las Americas, Melia Varadero, Sol Palmeras (Varadero) and Melia Trinidad Península (Trinidad) hotels, and the 56,000m2 Miramar Trade Center office and retail complex in Havana. As at 31 March 2025, the unaudited net asset value of the Company was USD130,568,602 (31 December 2024: USD 129,968,866), which amount took into consideration deferred management fees payable to Aberdeen in the total amount of US$3,129,937 and the indebtedness to Bondholders of €25 million.

 

For further information, please contact:

 

Sebastiaan Berger

 

Via NSM Funds Limited

Singer Capital Markets

James Maxwell / Patrick Weaver (Corporate Finance)

James Waterlow (Sales)

 

Tel: +44 (0)20 7496 3000

NSM Funds Limited

Tel: +44 (0)1481 743030

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STREASXXEDNSEFA
12
Date   Source Headline
5th Jun 20268:33 amRNSTrading Update
27th May 20263:39 pmRNSHolding(s) in Company
22nd May 20262:30 pmRNSHolding(s) in Company
20th May 20263:37 pmRNSHolding(s) in Company
19th May 20261:07 pmRNSHolding(s) in Company
15th May 202612:40 pmRNSDirector/PDMR Shareholding
12th May 20267:00 amRNSIssue of Equity
30th Apr 20267:00 amRNSAnnual Financial Report
14th Apr 20264:46 pmRNSResult of EGM
1st Apr 202611:21 amRNSFurther re Second Amendment of Bond Instrument
27th Feb 20265:14 pmRNSFurther re Second Amendment of Bond Instrument
27th Feb 20262:26 pmRNSDirectorate change
13th Feb 20265:13 pmRNSStatement re Second Amendment of Bond Instrument
13th Feb 20263:20 pmRNSDirector Declaration
12th Feb 20265:32 pmRNSChange of Auditor
5th Feb 20267:00 amRNSTrading Update - Consultation with Bondholders
26th Jan 20263:36 pmRNSDirector/PDMR Shareholding
23rd Dec 20251:39 pmRNSNet Asset Value(s)
4th Dec 20253:25 pmRNSAppointment of Senior Independent Director
2nd Oct 20252:48 pmRNSDirector/PDMR Shareholding
29th Sep 20257:00 amRNSHalf-year Report
12th Sep 20253:16 pmRNSDirectorate Change
8th Jul 20257:00 amRNSTrading Update - Payment to Bondholders
4th Jul 202512:49 pmRNSDirectorate Change
3rd Jul 20253:14 pmRNSResult of AGM
1st Jul 20251:35 pmRNSNet Asset Value(s)
30th Apr 20257:00 amRNSAnnual Financial Report
28th Apr 202510:26 amRNSDirectorate Change
3rd Feb 20257:00 amRNSStatement re Amendment of Bond Instrument
13th Jan 20255:51 pmRNSStatement re Amendment of Bond Instrument
11th Dec 20241:31 pmRNSNet Asset Value(s)
7th Oct 202410:55 amRNSDirector/PDMR Shareholding
7th Oct 20247:00 amRNSStatement re Update from the Chairman
27th Sep 20247:00 amRNSHalf-year Report to 30 June 2024
13th Aug 20248:36 amRNSDirectorate Change
20th Jun 20243:09 pmRNSDirector/PDMR Shareholding
20th Jun 20247:00 amRNSNet Asset Value(s)
18th Jun 20244:53 pmRNSResult of AGM
30th Apr 20247:00 amRNSAnnual Financial Report
25th Mar 202411:03 amRNSDirectorate Change
17th Jan 20247:00 amRNSInvestment Update
27th Dec 20239:17 amRNSNet Asset Value(s)
18th Dec 20238:54 amRNSDirector/PDMR Shareholding
3rd Nov 202310:36 amRNSHolding(s) in Company
1st Nov 20239:05 amRNSDirector/PDMR Shareholding
27th Oct 202311:11 amRNSDirector/PDMR Shareholding
16th Oct 20238:37 amRNSAppointment of Non-Executive Director
12th Oct 20234:26 pmRNSDirector/PDMR Shareholding
5th Oct 202310:24 amRNSDirector/PDMR Shareholding
29th Sep 20237:00 amRNSHalf-year Report
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.